Published in Liver Cancer on November 01, 2012
Stapler Hepatectomy for Elective Liver Resection (CRUNSH) | NCT01049607
Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open (2015) 1.43
Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer (2013) 1.21
Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer (2014) 1.07
The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int (2014) 1.03
Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med (2014) 0.99
Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol (2015) 0.98
Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol (2014) 0.97
Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer (2013) 0.95
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer (2015) 0.95
Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer. Oncotarget (2015) 0.89
Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer (2015) 0.86
MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27. Int J Clin Exp Med (2014) 0.86
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol (2015) 0.86
Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells. Oncotarget (2015) 0.85
Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med (2015) 0.84
Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Mol Cancer Ther (2015) 0.81
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol (2016) 0.81
Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett (2014) 0.81
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. PLoS One (2014) 0.80
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci (2017) 0.80
Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI. Liver Cancer (2015) 0.80
Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma. Surg Endosc (2014) 0.79
Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag (2016) 0.79
Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells. Cell Stress Chaperones (2016) 0.79
Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction. BMC Gastroenterol (2015) 0.78
Current Treatment Approaches to HCC with a Special Consideration to Transplantation. J Transplant (2016) 0.78
MicroRNA-23b functions as an oncogene and activates AKT/GSK3β/β-catenin signaling by targeting ST7L in hepatocellular carcinoma. Cell Death Dis (2017) 0.77
A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine. World Neurosurg (2016) 0.77
ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Int J Clin Exp Med (2015) 0.77
Intrahepatic Tissue Implantation Represents a Favorable Approach for Establishing Orthotopic Transplantation Hepatocellular Carcinoma Mouse Models. PLoS One (2016) 0.77
A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. J Hepatocell Carcinoma (2014) 0.76
Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma. Clinics (Sao Paulo) (2015) 0.75
Meta-analysis of the prognostic value of abnormally expressed lncRNAs in hepatocellular carcinoma. Onco Targets Ther (2016) 0.75
How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer (2016) 0.75
Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma. Am J Cancer Res (2017) 0.75
Preliminary results of ultrasound-guided laser ablation for unresectable metastases to retroperitoneal and hepatic portal lymph nodes. World J Surg Oncol (2016) 0.75
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res (2014) 0.75
V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy. Oncotarget (2016) 0.75
Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis. Oncol Lett (2017) 0.75
A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget (2016) 0.75
A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC). Transl Gastroenterol Hepatol (2016) 0.75
EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma Cells In Vitro via Inhibiting the Phosphorylation of Src. Biomed Res Int (2016) 0.75
Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience. J Gastrointest Cancer (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology (2008) 8.24
A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med (1995) 6.75
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2010) 4.75
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (2011) 3.73
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg (2003) 3.16
Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg (1991) 3.12
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Management of HCC. J Hepatol (2012) 3.03
Liver transplantation from live donors. Lancet (1989) 2.98
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut (2003) 2.96
Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol (2010) 2.81
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst (2005) 2.73
Successful liver transplantation from a living donor to her son. N Engl J Med (1990) 2.58
A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol (2012) 2.53
Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg (2006) 2.52
Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg (2011) 2.51
Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg (2008) 2.31
Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther (2009) 2.31
Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol (2010) 2.31
Determination of the hepatic arterial blood flow and oxygen supply in man by clamping the hepatic artery during surgery. J Clin Invest (1962) 2.26
Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl (2008) 2.22
Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg (2003) 2.21
Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer (2008) 2.18
Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg (2000) 2.13
Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology (2010) 2.08
Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer (2001) 1.94
Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol (2007) 1.93
The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist (2010) 1.84
Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer (1988) 1.83
Laparoscopic resection for hepatocellular carcinoma: a matched-pair comparative study. Surg Endosc (2009) 1.78
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist (2012) 1.76
The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis. Liver Transpl (2011) 1.75
The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol (2009) 1.67
Laparoscopic liver resection: benefits and controversies. Surg Clin North Am (2004) 1.62
Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology (2004) 1.61
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology (2001) 1.53
Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. Eur J Surg Oncol (2010) 1.49
Successful living-related partial liver transplantation to an adult patient. Lancet (1994) 1.47
Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol (2008) 1.43
Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol (2010) 1.41
Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg (2007) 1.38
Stapler hepatectomy is a safe dissection technique: analysis of 300 patients. World J Surg (2006) 1.38
Outcome for patients treated with laparoscopic versus open resection of hepatocellular carcinoma: case-matched analysis. Ann Surg Oncol (2009) 1.34
Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol (2008) 1.33
Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol (2009) 1.31
Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer (2010) 1.30
Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut (2002) 1.29
Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery (2002) 1.28
Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg (1987) 1.28
Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol (2011) 1.27
Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant (2008) 1.27
Systematic review and meta-analysis of the effect of portal triad clamping on outcome after hepatic resection. Br J Surg (2008) 1.27
Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol (2010) 1.25
Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology (2012) 1.24
Laparoscopic versus open liver resection: a matched-pair case control study. J Gastrointest Surg (2009) 1.23
Staging and current treatment of hepatocellular carcinoma. Radiographics (2005) 1.23
Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol (2011) 1.22
Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol (2010) 1.21
Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol (2008) 1.18
"State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. World J Surg (2009) 1.18
Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer (2000) 1.14
Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer (1985) 1.12
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther (2008) 1.12
Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol (2010) 1.12
Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant (2009) 1.11
The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer (2012) 1.11
Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol (2012) 1.10
Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol (2012) 1.10
Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J Cancer Res Clin Oncol (2012) 1.08
Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl (2012) 1.06
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer (2002) 1.06
Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery (2012) 1.04
Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer (2009) 1.03
Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases. J Gastrointest Surg (2010) 1.03
Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol (2007) 1.03
Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol (2008) 1.02
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16
Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR -- how well do they correlate? BMC Genomics (2005) 2.76
Ageing-related chromatin defects through loss of the NURD complex. Nat Cell Biol (2009) 2.40
The supramolecular chemistry of organic-inorganic hybrid materials. Angew Chem Int Ed Engl (2006) 2.22
Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation (2003) 2.12
Primary ciliary dyskinesia associated with normal axoneme ultrastructure is caused by DNAH11 mutations. Hum Mutat (2008) 2.03
Mutations of the catalytic subunit of RAB3GAP cause Warburg Micro syndrome. Nat Genet (2005) 1.98
Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra? Stroke (2003) 1.90
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol (2012) 1.90
Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology (2014) 1.76
Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. Brain (2010) 1.76
The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol (2005) 1.73
Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol (2009) 1.70
Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation (2004) 1.52
Mutation in the ARH gene and a chromosome 13q locus influence cholesterol levels in a new form of digenic-recessive familial hypercholesterolemia. Circ Res (2002) 1.52
Thioredoxin in human and experimental sepsis. Crit Care Med (2009) 1.51
Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension (2011) 1.46
Occult cytomegalovirus cholangitis as a potential cause of cholestatic complications after orthotopic liver transplantation? A study of cytomegalovirus DNA in bile. Liver Transpl (2013) 1.42
Feasibility and effectiveness of a new algorithm in preventing hepatic artery thrombosis after liver transplantation. J Gastrointest Surg (2008) 1.41
Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol (2004) 1.41
Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice. Exp Neurol (2007) 1.40
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res (2010) 1.40
Fulminant hepatic failure: etiology and indications for liver transplantation. Nephrol Dial Transplant (2007) 1.39
Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders. Am J Hum Genet (2008) 1.34
Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology (2012) 1.29
CA8 mutations cause a novel syndrome characterized by ataxia and mild mental retardation with predisposition to quadrupedal gait. PLoS Genet (2009) 1.27
Association of FTO variants with BMI and fat mass in the self-contained population of Sorbs in Germany. Eur J Hum Genet (2010) 1.26
Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One (2012) 1.25
Mutations at the mouse ichthyosis locus are within the lamin B receptor gene: a single gene model for human Pelger-Huët anomaly. Hum Mol Genet (2003) 1.22
Faulty initiation of proteoglycan synthesis causes cardiac and joint defects. Am J Hum Genet (2011) 1.20
L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr Opin Clin Nutr Metab Care (2003) 1.16
Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs. Hum Mol Genet (2009) 1.16
Ischemia/Reperfusion injury in liver surgery and transplantation: pathophysiology. HPB Surg (2012) 1.12
Marfan syndrome with neonatal progeroid syndrome-like lipodystrophy associated with a novel frameshift mutation at the 3' terminus of the FBN1-gene. Am J Med Genet A (2010) 1.08
Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol (2012) 1.08
Signs of reperfusion injury following CO2 pneumoperitoneum: an in vivo microscopy study. Surg Endosc (2007) 1.08
Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett (2008) 1.05
High-throughput sequencing of microdissected chromosomal regions. Eur J Hum Genet (2009) 1.04
GENOMIZER: an integrated analysis system for genome-wide association data. Hum Mutat (2006) 1.03
Results of renal transplantation using kidneys harvested from living donors at the University of Heidelberg. Nephrol Dial Transplant (2004) 1.02
Cell death biomarkers as early predictors for hepatic dysfunction in patients after orthotopic liver transplantation. Transplantation (2012) 1.02
Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Int J Cancer (2014) 1.01
Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-kB and apoptosis after experimental kidney transplantation. J Pineal Res (2009) 1.00
Reactive metabolites and AGE-RAGE-mediated inflammation in patients following liver transplantation. Mediators Inflamm (2013) 0.99
On the TRAIL to therapeutic intervention in liver disease. Hepatology (2007) 0.98
Scientific evidence for application of topical hemostats, tissue glues, and sealants in hepatobiliary surgery. J Am Coll Surg (2005) 0.97
A case of palytoxin poisoning due to contact with zoanthid corals through a skin injury. Toxicon (2008) 0.97
The comparison of 2-dimensional with 3-dimensional hepatic visualization in the clinical hepatic anatomy education. Medicina (Kaunas) (2008) 0.97
Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation. Endoscopy (2013) 0.96
Surgical treatment of primary hepatic epithelioid hemangioendothelioma. Transplantation (2005) 0.96
Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. Oncotarget (2014) 0.96
Suitability of human mesenchymal stem cells for gene therapy depends on the expansion medium. Exp Cell Res (2008) 0.95
Behavioral alterations in a mouse model of temporal lobe epilepsy induced by intrahippocampal injection of kainate. Exp Neurol (2008) 0.95
Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol (2010) 0.94
Hepaticojejunostomy--analysis of risk factors for postoperative bile leaks and surgical complications. J Gastrointest Surg (2007) 0.93
Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. Neuropharmacology (2008) 0.93
Osteopoikilosis and multiple exostoses caused by novel mutations in LEMD3 and EXT1 genes respectively--coincidence within one family. BMC Med Genet (2010) 0.92
Is veno-venous bypass still needed during liver transplantation? A review of the literature. Clin Transplant (2009) 0.92
Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis. Cancer Med (2013) 0.91
Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation. Clin Transplant (2006) 0.91
Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clin Transplant (2013) 0.90
Mutations causing Greenberg dysplasia but not Pelger anomaly uncouple enzymatic from structural functions of a nuclear membrane protein. Nucleus (2010) 0.89
ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation (2012) 0.89
The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res (2011) 0.89
Dietary omega-3-polyunsaturated fatty acids prevent the development of metastases of colon carcinoma in rat liver. Eur J Nutr (2007) 0.87
Efficient two-trait-locus linkage analysis through program optimization and parallelization: application to hypercholesterolemia. Eur J Hum Genet (2004) 0.87
S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. Drug Metab Dispos (2006) 0.87
Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol (2007) 0.87
Hepatobiliary malignancies in Wilson disease. Liver Int (2014) 0.87
Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation. J Surg Res (2007) 0.86
Quality of life after curative liver resection: a single center analysis. World J Gastroenterol (2010) 0.86
Synergistic effects of miconazole and polymyxin B on microbial pathogens. Vet Res Commun (2008) 0.86
Living-donor liver transplantation: evaluation of donor and recipient. Nephrol Dial Transplant (2004) 0.86
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology (2013) 0.86
Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia (2008) 0.86
Long-term results of paediatric kidney transplantation at the University of Heidelberg: a 35 year single-centre experience. Nephrol Dial Transplant (2004) 0.85
Unique cell type-specific junctional complexes in vascular endothelium of human and rat liver sinusoids. PLoS One (2012) 0.85
Hidden population substructures in an apparently homogeneous population bias association studies. Eur J Hum Genet (2006) 0.85
Indications for intestinal transplantation: recognizing the scope and limits of total parenteral nutrition. Clin Transplant (2013) 0.84
Allogeneic blood transfusion does not affect outcome after curative resection for advanced cholangiocarcinoma. Ann Surg Oncol (2013) 0.84
Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study. Microcirculation (2011) 0.84
Liver transplantation for hepatocellular carcinoma: is there evidence for expanding the selection criteria? Transplantation (2005) 0.84
Rational design of a chromo- and fluorogenic hybrid chemosensor material for the detection of long-chain carboxylates. J Am Chem Soc (2005) 0.84
Persistent ascites after liver transplantation: etiology, treatment and impact on survival. Ann Transplant (2013) 0.84
Partial liver transplantation-living donor liver transplantation and split liver transplantation. Nephrol Dial Transplant (2007) 0.84
HPGD mutations cause cranioosteoarthropathy but not autosomal dominant digital clubbing. Eur J Hum Genet (2009) 0.84
Controlled-surgical education in clinical liver transplantation is not associated with increased patient risks. Clin Transplant (2006) 0.83
Sulforaphane and related mustard oils in focus of cancer prevention and therapy. Wien Med Wochenschr (2012) 0.83
Pretransplant model for end stage liver disease score predicts posttransplant incidence of fungal infections after liver transplantation. Mycoses (2013) 0.83
Dietary glycine protects from chemotherapy-induced hepatotoxicity. Amino Acids (2010) 0.83
Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Transplantation (2015) 0.82
Factors predictive of survival after stapler hepatectomy of hepatocellular carcinoma: a multivariate, single-center analysis. Anticancer Res (2014) 0.82
Sulforaphane decreases kidney injury after transplantation in rats: role of mitochondrial damage. Ann Transplant (2013) 0.82
Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation. J Pineal Res (2008) 0.82
Utilization of extended donor criteria in liver transplantation: a comprehensive review of the literature. Nephrol Dial Transplant (2007) 0.82
A routine liver transplantation in a patient with situs inversus: a case report and an overview of the literature. Clin Transplant (2006) 0.82